Acasti Pharma Inc (NAS:ACST)
$ 3.3 0.15 (4.76%) Market Cap: 31.02 Mil Enterprise Value: 4.52 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 41/100

Acasti Pharma Inc Announces Positive Results for Pharmacokinetic Bridging Study Call Transcript

May 18, 2022 / 05:00PM GMT
Release Date Price: $5.76 (-0.77%)
Operator

Good day, ladies and gentlemen, and welcome to the Acasti Pharma Clinical and Business Update Conference Call. (Operator Instructions)

It is now my pleasure to turn the floor over to your host, Natalya Rudman, Investor Relations. Ma'am, the floor is yours.

Natalya Rudman
Crescendo Communications, LLC - Senior VP & Director of Market Intelligence

Thank you, and good afternoon, everyone. I'd like to welcome you to Acasti Pharma's Clinical Update Conference Call. On the call with us this afternoon are Jan D'Alvise, President and CEO; Dr. Pierre Lemieux, Chief Operating Officer, Canada and Chief Scientific Officer; Dr. George Kottayil, Chief Operating Officer, U.S.; and Prashant Kohli, Vice President of Commercial Operations.

Following our prepared remarks, there will be a Q&A session. Should any questions remain after the call, please contact Crescendo Communications at (212) 671-1020. And I'd also like to remind everyone that statements on this conference call that are not statements of historical or current facts constitute forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot